相关实验视频
Updated: Mar 4, 2026

05:39
Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
Published on: May 16, 2025
759
杜皮卢马布改善了成年患者的每日症状负担 Prurigo Nodularis:从LIBERTY PN-PRIME和PRIME2研究的后期分析
Shawn G Kwatra1, Sonja Ständer2, Brian S Kim3
1Maryland Itch Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Dermatology and therapy
|March 2, 2026
概括
杜皮卢马布显著减少了prurigo nodularis患者的每日症状负担,改善了,皮肤疼痛和睡眠. 这种治疗为那些患有无法控制的慢性的人提供了有意义的缓解.
科学领域:
- 皮肤病学 皮肤病学
- 临床试验 临床试验
- 患者报告的结果
背景情况:
- 结 (prurigo nodularis,简称PN) 是一种慢性皮肤疾病,会引起强烈的和结节.
- 局部疗法往往不足以控制不受控制的PN.
- 杜比卢马布此前已经在减少PN患者的方面表现出有效性.
研究的目的:
- 评估dupilumab对PN患者每日症状负担 (DSB) 的影响.
- 评估,皮肤疼痛和睡眠障碍的改善情况.
- 为了比较dupilumab与安慰剂在减少PN症状强度方面.
主要方法:
- 分析了来自PRIME和PRIME2临床试验 (N=311) 的数据.
- 每天的症状负担使用最坏的 numeric评分尺度 (WI-NRS),皮肤疼痛-NRS和睡眠-NRS (0-10级) 进行了测量.
- 没有至轻度症状的患者的比例和有此类症状的平均日数被比较到第24周.
主要成果:
- 在dupilumab患者中,显著更高的比例在24周 (p<0.0001) 经历了无至轻度 (26.8%vs7.6%),皮肤疼痛 (38.6%vs19.0%) 和睡眠障碍 (28.8%vs10.1%).
- 杜皮卢马布治疗导致每周有更多的无至轻度症状: (2.4 vs 0.9),皮肤疼痛 (3.4 vs 1.9) 和睡眠障碍 (2.7 vs 1.4).
结论:
- 与安慰剂相比,dupilumab在减轻PN的每日症状负担方面表现出更高的疗效.
- 接受dupilumab的患者在,皮肤疼痛和睡眠质量方面经历了显著改善.
- 杜皮卢马布为患有节的患者的症状管理提供了一个有前途的治疗选择.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
800
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
800
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
614
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
614
Inflammatory Bowel Disease IV: Pharmacological Management
868
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
868
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
664
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
664